Follow The Filings

ABCL Abcellera Biologics Inc.

Health Care, filed as Abcellera Biologics Inc (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by ABCL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ABCL insider trades
  • $2.7M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Michael R Hayden Director
    Buy
    $570K 53,613 shares at $10.64 +4.1% to stake
    Traded Aug 24 Filed Aug 24
    ↗
  2. John S. Montalbano Director
    Buy
    $110K 10,000 shares at $11.03 +4.1% to stake
    Traded Aug 18 Filed Aug 18
    ↗
  3. Andrew Booth CFO
    Buy
    $384K 37,200 shares at $10.32 +8.3% to stake
    Traded Aug 14 Filed Aug 14
    ↗
  4. Michael R Hayden Director
    Buy
    $481K 46,387 shares at $10.37 +3.6% to stake
    Traded Aug 12 Filed Aug 14
    ↗
  5. John S. Montalbano Director
    Buy
    $95K 20,000 shares at $4.77 +9% to stake
    Traded May 14 Filed May 18
    ↗
  6. Thermopylae Holdings Ltd. 10% owner
    Buy
    $131K 38,000 shares at $3.44 +0.1% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  7. Thermopylae Holdings Ltd. 10% owner
    Buy
    $580K 177,457 shares at $3.27 +0.3% to stake
    Traded Feb 26 Filed Feb 27
    ↗
  8. Andrew Booth CFO
    Buy
    $146K 42,600 shares at $3.42 +28% to stake
    Traded Feb 27 Filed Feb 27
    ↗
  9. John S. Montalbano Director
    Buy
    $178K 50,000 shares at $3.57 +29% to stake
    Traded Nov 26, 2025 Filed Nov 26, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 gifts and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $38.02M $28.83M $75.13M
Net income -$146.4M -$162.86M -$146.41M
Net margin * -385.0% -564.8% -194.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $871.98M $751.37M $728.23M
Total non-current assets $616.11M $609.18M $628.72M
Total assets $1.49B $1.36B $1.36B
Total current liabilities $119.01M $76.61M $64.31M
Total non-current liabilities $216.76M $227.86M $325.74M
Total equity $1.15B $1.06B $0.967B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$43.88M -$108.56M -$131.3M
Cash from investing -$221.11M $121.41M $87.75M
Cash from financing $10.36M $12.77M $14.08M
Net change in cash -$254.04M $23M -$28.37M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.